The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
Open accessAbstract
About 20% to 40% of patients with breast cancer eventually develop recurrences in distant organs, which are often not detected until years to decades after the primary tumor diagnosis. This phenomenon is especially pronounced in estrogen receptor–positive (ER+) breast cancer, suggesting that ER+ cancer cells may stay dormant for a protracted period of time, despite adjuvant therapies. Multiple mechanisms have been proposed to explain how cancer cells survive and remain in dormancy, and how they become reactivated and exit dormancy. These mechanisms include angiogenic switch, immunosurveillance, and interaction with extracellular matrix and stromal cells. How to eradicate or suppress these dormant cancer cells remains a major clinical issue because of the lack of knowledge about the biologic and clinical nature of these cells. Herein, we review the clinical manifestation of metastasis dormancy in ER+ tumors, the current biologic insights regarding tumor dormancy obtained from various experimental models, and the clinical challenges to predict, detect, and treat dormant metastases. We also discuss future research directions toward a better understanding of the biologic mechanisms and clinical management of ER+ dormant metastasis. Clin Cancer Res; 19(23); 6389–97. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Colleoni, M., Sun, Z., Price, K. N., Karlsson, P., Forbes, J. F., Thürlimann, B., Gianni, L., Castiglione, M., Gelber, R. D., Coates, A. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3504 · Cited by 613
A framework for the development of effective anti-metastatic agents
Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0134-8 · Cited by 341
Qureshi, R., Picon-Ruiz, M., Sho, M., Van Booven, D., Nunes de Paiva, V., Diaz-Ruano, A. B., Ince, T. A., & Slingerland, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111672 · Cited by 37
Metadata
- Authors
- Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R., & Osborne, C. K.
- Venue
- Clinical Cancer Research
- Published
- 2013-12-01
- Volume
- 19
- Issue
- 23
- Pages
- 6389-6397
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2159303972
- Cited by
- 264
- References
- 57
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-0838
- The paper
- Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R., & Osborne, C. K. (2013). Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-0838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.